Let's see whats new in the market
As part of the agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party quality controls as well as the LabLink xL web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. Customers will further gain access to additional features, such as support, service, and quality control ranges for specific reagent slots which are not currently available through other quality control problems
On 14 July Kromek announced it has received new contracts and repeated orders across all its target segments, such as purchases of the group’s D5 RIID high-performance radiation detector and its D3S ID portable radiation detector. All of the contracts are incorporated in the group’s current financial year.
As a leading developer of wearable and radiation detectors, KROMEK was invited to participate in the multi-agency PARTIOT 21 exercise earlier in June. The exercise was conducted at the Volk Field Air National Guard base in Camp Douglas, Wisconsin, USA between the 15-17th of June. As part of the exercise, KROMEK’s products, such as the D3S ID detector was put to the test under different scenarios.
Looking to address medical needs and reducing development and preparedness costs for US taxpayers, the Biomedical Advanced Research and Development Authority recently purchased and began accepting Paratek Pharmaceuticals’ NUZRYA antibiotic used to treat anthrax infections. Using the authorities and funding of Project BioShield, BARDA awarded Paratek the contract as early as 2019, potentially totalling up to $285 Million over a span of 10 years for the development of anthrax post-exposure drugs and their regulatory approval.
At the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Bruker launched new products and methods for their market leading MALDI Biotyper® (MBT) platform. The new MBT Lipid Xtract™ kit expands the current research capabilities into rapid lipid testing, taking the product beyond microbial identification.
The study, conducted by researchers at the Dutch TNO CBRN Protection Department, aims to verify the utility of the nonapeptide method used for the characterisation of human plasma samples which are exposed to Novichok nerve agents A-230/232/234. Then, by applying precursor ion scanning and high-resolution mass spectrometry tests, the researchers aim to evaluate possibilities of identifying unknown exposures
As part of the National Institute of Allergy and Infectious Diseases (NIAID) focus on discovery and development of antivirals against the Covid-19 and one or more identified RNA viruses with pandemic potential, the institute is seeking to establish the Antiviral Drug Discovery (AViDD) program, consisting of several, multidisciplinary centers.
Exensor Technology, a subsidiary of Bertin Technologies was selected once more by the Swedish Armed Forces for the supply of the Flexnet Unattended Ground Sensor (UGS) system. As part of the contract, Exensor Technology will provide the Swedish Armed Forces with a large number of tactical modular ground sensor systems that can be used to detect, classify, and identify potential ground threats.
At Bruker’s virtual 4D-Proteomics™ eXceed Symposium, Bruker Corporation announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Bruker’s collaborators are making major progress in unbiased single cell proteomics, phosphoproteomics and plasma proteomics, leveraging the speed, sensitivity and dynamic range of large-scale CCS-enabled 4D-Proteomics and 4D-Epiproteomics.